EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Emergent BioSolutions Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCM Products | $456.70M | $509.80M | $447.20M | $579.60M | $585.90M | – | – | – | – | – | 61.5% | -10.4% |
| Commercial Products | $226.10M | $398.90M | $497.30M | $386.60M | $438.00M | – | – | – | – | – | 30.4% | -43.3% |
| Products | – | – | – | $966.20M | $1.02B | $989.80M | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and services sales, net | $705.20M | $1.01B | $1.02B | – | – | – | – | – | – | – | 94.9% | -30.4% |
| MCM Product sales | $456.70M | $509.80M | $447.20M | $579.60M | $585.90M | – | – | – | – | – | 61.5% | -10.4% |
| Commercial Product sales | $226.10M | $398.90M | $497.30M | $386.60M | $438.00M | – | – | – | – | – | 30.4% | -43.3% |
| All other revenue | $60.10M | $134.90M | $104.80M | – | – | – | – | – | – | – | 8.1% | -55.4% |
| Contracts and grants | $37.70M | $30.00M | $26.30M | $41.40M | $134.20M | $115.10M | $122.50M | $77.00M | $70.50M | $143.40M | 5.1% | +25.7% |
| CDMO | – | – | – | – | – | $450.50M | $80.00M | $98.90M | $68.90M | $49.10M | – | – |
| Products | – | $908.70M | $944.50M | $966.20M | $1.02B | $989.80M | $903.50M | $606.50M | $421.50M | $296.30M | – | – |
| CDMO | – | – | – | – | – | $450.50M | $80.00M | $98.90M | $68.90M | – | – | – |
| Service | – | $103.50M | $72.80M | $105.00M | $310.30M | $194.10M | $80.00M | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $531.10M | $822.60M | $607.20M | $886.10M | $1.62B | $1.47B | $674.70M | $597.60M | $439.90M | $421.30M | 71.5% | -35.4% |
| Other | $136.80M | $80.60M | $217.90M | $82.80M | $83.50M | $63.40M | – | – | – | – | 18.4% | +69.7% |
| Canada | $75.00M | $140.40M | $224.20M | $148.60M | $66.70M | $46.00M | – | – | – | – | 10.1% | -46.6% |
| Non-US | – | – | – | – | $894.90M | $566.90M | $431.30M | $184.80M | $121.00M | $67.50M | – | – |
From the segment and revenue-disaggregation notes of Emergent BioSolutions's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.